Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

Positive Results Announced for Pleuromutilin Antibiotic in CABP

Positive Results Announced for Pleuromutilin Antibiotic in CABP

By

In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days.

AAP Recommends Shot Over Nasal Spray for 2018-2019 Flu Season

AAP Recommends Shot Over Nasal Spray for 2018-2019 Flu Season

By

The advisory comes early as physicians are currently placing vaccine orders.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

FDA Announces New Initiative Aimed at Stopping Youth Use of E-Cigarettes

FDA Announces New Initiative Aimed at Stopping Youth Use of E-Cigarettes

By

In a wide ranging statement, the FDA commissioner Scott Gottlieb, MD, specifically targets novel nicotine-delivery products as being problematic since many of these devices resemble USB flash drives, have high nicotine levels and have emissions that are hard to see.

Dacomitinib Granted Priority Review for NSCLC With EGFR-Activating Mutations

Dacomitinib Granted Priority Review for NSCLC With EGFR-Activating Mutations

By

Dacomitinib is a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

More Articles by Steve Duffy

Sign Up for Free e-newsletters